[go: up one dir, main page]

NO20023878L - Fremgangsmåte for å identifisere og anvende A2B adenosinreseptorantagonister for å formidle mammalskcelleproliferering - Google Patents

Fremgangsmåte for å identifisere og anvende A2B adenosinreseptorantagonister for å formidle mammalskcelleproliferering

Info

Publication number
NO20023878L
NO20023878L NO20023878A NO20023878A NO20023878L NO 20023878 L NO20023878 L NO 20023878L NO 20023878 A NO20023878 A NO 20023878A NO 20023878 A NO20023878 A NO 20023878A NO 20023878 L NO20023878 L NO 20023878L
Authority
NO
Norway
Prior art keywords
identifying
cell proliferation
mammalian cell
receptor antagonists
adenosine receptor
Prior art date
Application number
NO20023878A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023878D0 (no
Inventor
Luiz Belardinelli
Maria B Grant
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20023878L publication Critical patent/NO20023878L/no
Publication of NO20023878D0 publication Critical patent/NO20023878D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20023878A 2000-02-17 2002-08-15 Fremgangsmåte for å identifisere og anvende A2B adenosinreseptorantagonister for å formidle mammalskcelleproliferering NO20023878D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18314100P 2000-02-17 2000-02-17
PCT/US2001/004917 WO2001060350A2 (fr) 2000-02-17 2001-02-16 Procede d'identification et d'utilisation d'antagonistes du recepteur d'adenosine a2b pour agir sur la proliferation cellulaire d'un mammifere

Publications (2)

Publication Number Publication Date
NO20023878L true NO20023878L (no) 2002-08-15
NO20023878D0 NO20023878D0 (no) 2002-08-15

Family

ID=22671613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023878A NO20023878D0 (no) 2000-02-17 2002-08-15 Fremgangsmåte for å identifisere og anvende A2B adenosinreseptorantagonister for å formidle mammalskcelleproliferering

Country Status (13)

Country Link
US (1) US6894021B2 (fr)
EP (1) EP1255550A2 (fr)
JP (1) JP2003535818A (fr)
KR (1) KR20030031466A (fr)
CN (1) CN1420775A (fr)
AU (1) AU2001238342A1 (fr)
BR (1) BR0108454A (fr)
CA (1) CA2400206A1 (fr)
IL (1) IL151160A0 (fr)
MX (1) MXPA02007761A (fr)
NO (1) NO20023878D0 (fr)
WO (1) WO2001060350A2 (fr)
ZA (1) ZA200206582B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
EP1658291B1 (fr) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Xanthines de 8-heteroaryle substituees
RS52455B (sr) * 2004-09-01 2013-02-28 Gilead Sciences Inc. Postupak zarastanja rana primenom antagonista adenozinskog a2b receptora
US20060159627A1 (en) 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091936A2 (fr) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique
WO2006091898A2 (fr) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Xanthines substituees par pyrazolyle
JP5044823B2 (ja) * 2005-06-16 2012-10-10 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US20070208042A1 (en) 2006-03-03 2007-09-06 Sherwood Services Ag Method of using vasoconstrictive agents during energy-based tissue therapy
US7767686B2 (en) * 2006-03-03 2010-08-03 Covidien Ag Method of using adenosine receptor blockers during tissue ablation
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
CN107407897B (zh) * 2015-03-30 2019-05-03 住友理工株式会社 电子照相设备用导电性部件

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
AU9040098A (en) * 1997-09-10 1999-03-29 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
EP1011608A4 (fr) * 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments
WO2000051621A1 (fr) * 1999-03-05 2000-09-08 Epigenesis Pharmaceuticals, Inc. Procede de validation/d'invalidation de cibles et des voies
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors

Also Published As

Publication number Publication date
JP2003535818A (ja) 2003-12-02
US6894021B2 (en) 2005-05-17
WO2001060350A3 (fr) 2002-04-04
IL151160A0 (en) 2003-04-10
CA2400206A1 (fr) 2001-08-23
KR20030031466A (ko) 2003-04-21
MXPA02007761A (es) 2002-10-11
WO2001060350A2 (fr) 2001-08-23
US20020002142A1 (en) 2002-01-03
AU2001238342A1 (en) 2001-08-27
ZA200206582B (en) 2003-04-09
BR0108454A (pt) 2003-04-01
EP1255550A2 (fr) 2002-11-13
NO20023878D0 (no) 2002-08-15
CN1420775A (zh) 2003-05-28

Similar Documents

Publication Publication Date Title
NO20023878D0 (no) Fremgangsmåte for å identifisere og anvende A2B adenosinreseptorantagonister for å formidle mammalskcelleproliferering
AU7524601A (en) T cell receptor fusions and conjugates and methods of use thereof
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
EE200000294A (et) Tsüklilised amiini derivaadid ning meetod kemokiini seondumise sihtraku retseptoriga ja/või kemokiini toime sihtrakule inhibeerimiseks
NO20011303L (no) Fremgangsmåter for nukleinsyreoppformering og sekvensering
AU5316000A (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
AU6808901A (en) Adenosine a2a receptor antagonists
IL176010A0 (en) Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
ID25613A (id) Metode untuk menghasilkan purin nukleosida melalui fermentasi
NO20034580D0 (no) Fremgangsmåte og reagenser for celletransplantasjon
IL160706A0 (en) Peptides acting as both glp-1 receptor agonists and their pharmacological methods of use
DK0973997T3 (da) Fremgangsmåde og anordning til sammensætningsanalyse af formationsgasser i borehuller
IS6183A (is) Díamínóþíazol og notagildi þeirra til að hindra prótín kínasa
IL157428A0 (en) Bipiperidinyl derivatives and their use as chemokine receptor inhibitors
HUP0302339A3 (en) Mammalian receptor subunit proteins, related reagents and methods
DK1465634T3 (da) Fremgangsmåde til anvendelse af adenosinreceptorinhibitorer til at forstærke immunrespons og inflammation
TWI365879B (en) A2b adenosine receptor antagonists
AU2001274920A1 (en) Mammalian receptor proteins; related reagents and methods
IL174771A0 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
AU6488901A (en) Human receptor proteins; related reagents and methods
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
AU2003239199A8 (en) System and method for testing response to asynchronous system errors
EP1346028A4 (fr) Appareil de culture cellulaire et procedes d'utilisation
IL151620A0 (en) Methods of making and using microarrays of anti-ligands for the analysis of protein expression in cells
AU2003254003A8 (en) Pr/set-domain containing nucleic acids, polypeptides, antibodies and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application